Drugs / PSA prostate cancer vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00005992 | Dec 2000 → ? | prostate cancer | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00015977 | Nov 2001 → Mar 2003 | prostate cancer | University of Chicago | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSA prostate cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005992 ↗ |
| Known as | CaPVax | “Patients receive rPSMA-pulsed autologous DC (CaPVax) intradermally.” NCT00005992 ↗ |
| Action | Deplete | “Vaccines made from a person's peripheral stem cells may make the body build an immune response to kill tumor cells.” NCT00005992 ↗ |
| Modality | Vaccine | “PSA prostate cancer vaccine” NCT00005992 ↗ |
| Route | Other | “Patients receive rPSMA-pulsed autologous DC (CaPVax) intradermally.” NCT00005992 ↗ |